目的:综合评价硼替佐米用于多发性骨髓瘤治疗的临床安全性、有效性、经济性、创新性、适宜性和可及性.方法:通过各级来源证据对指标进行整合分析.结果:纳入 6 篇meta分析和 5 篇药物经济学研究文章,采用硼替佐米方案治疗多发性骨髓瘤的总缓解率优于对照组,不良反应发生率为 64.06%,血小板减少和外周神经病变发生率较高.硼替佐米存储要求低、产能充足、部分厂家产品居民可负担性较好,但创新数据不足.结论:硼替佐米安全性、有效性明确,适宜性、可及性较好,部分方案成本效益较好.
Objective:To comprehensively evaluate the clinical safety,efficacy,economy,innovation,suitability and accessibility of bortezomib for the treatment of multiple myeloma.Methods:The indicators were analyzed in an integrated manner through evidence from all levels of sources.Results:Six systematic reviews/mata-analysis and 5 pharmacoeconomic studies were enrolled.The overall response rate in multiple myeloma patients treated with bortezomib were better than without,the incidence of adverse drug reaction was 64.06%,but the incidence of thrombocytopenia and peripheral neuropathy was higher.This study showed that bortezomib was convenient for storage with sufficient production capacity,and some products were good affordable,but lacked innovation data.Conclusion:Bortezomib is safe and effective,with good suitability and accessibility and some schemes are cost-effective.